Acute Lymphoblastic Leukaemias (ALL) Recruiting Phase 2 Trials for Clofarabine (DB00631)

Also known as: Acute Lymphoblastic Leukemias / Acute Leukemia, Lymphoblastic / Acute Lymphoblastic Leukaemia / Acute Lymphoblastic Leukemia / Leukemia, Lymphoblastic, Acute / Lymphoblastic Leukemia, Acute / Leukemia, Acute Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Acute Lymphoblastic Leukemia (ALL) / Leukemia, Lymphoblastic,Acute / Acute Leukaemia, Lymphoblastic / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02349178Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCTTreatment
NCT01119066HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesTreatment
NCT03136146Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)Treatment